Stem Cell Stocks Take Off (ASTM, GERN, OPXA, STEM)

Tickerspy’s Stem Cell Stock Index (*RSXTM) took off today, rising nearly 13%.  The movement followed a release from the National Institutes of Health  (NIH) announcing that 13 embryonic stem cell lines were approved for funding.

Opexa Therapeutics Inc (NASDAQ: OPXA) led the rise in stem cell stocks, surging over 40%.  The company seeks to develop treatments to major illnesses, such as multiple sclerosis and diabetes, through stem cell research.  The company’s stock has risen 2837% off its lows for the year.

StemCells Inc (NASDAQ: STEM) rose over 30% to a high of $1.45.  The company engages in research aimed at developing treatment for organ damage using stem cells.  The company’s stock is up over 1544% off its low for the year.

Garrett W. McIntyre